National and Kapodistrian University of Athens
Συσχέτιση των κλινικών αποτελεσμάτων με βάση την κύρια ένδειξη διακαθετηριακής σύγκλεισης παραβαλβιδικής ανεπάρκειας: αιμόλυση ή καρδιακή ανεπάρκεια
Abstract
dc:descriptionBackground: Paravalvular leak (PVL) is an important complication following surgical heart valve replacement and may present with symptoms of heart failure, hemolytic anemia, or a combination of both. Transcatheter paravalvular leak closure (TPVLC) is a therapeutic option for selected patients with increased surgical risk and suitable anatomy. Objective:The aim of this multicenter study was to investigate whether the primary clinical indication for transcatheter paravalvular leak closure—hemolysis or symptomatic heart failure—was associated with procedural effectiveness and mid-term patient outcomes. The study also examined the impact of PVL location on clinical outcomes and the long-term hematologic response of patients with hemolysis following the intervention. Methods: A retrospective multicenter study was conducted in patients who underwent TPVLC at five Greek centers. The co-primary endpoints were technical and clinical success according to the primary indication for the intervention. Secondary endpoints were technical and clinical success according to PVL location, as well as survival according to the primary indication and valve position. In the hemolysis subgroup, lactate dehydrogenase (LDH), hemoglobin, indirect bilirubin, transfusion requirement, and the occurrence of intervention-related hemolysis were assessed longitudinally. Survival was estimated using the Kaplan–Meier method. Results: A total of 76 patients were included, of whom 42 underwent TPVLC primarily for hemolysis and 34 for symptomatic heart failure. Technical success in the overall population was 92.1%, and clinical success was 81.6%. The prevalence of clinically significant grade III–IV PVL decreased from 85.5% before the intervention to 5.3% after the intervention (p < 0.001), while mean NYHA functional class improved from 2.95 ± 0.71 to 1.47 ± 0.74 (p < 0.001). Regarding the co-primary endpoints, no statistically significant difference was observed between the hemolysis and heart failure groups in technical success (88.1% vs. 97.1%, p = 0.150) or clinical success (73.8% vs. 91.2%, p = 0.052). Regarding the secondary endpoints, technical success did not differ significantly between aortic and mitral PVL (92.9% vs. 91.7%, p = 0.853). Similarly, no statistically significant difference was observed in clinical success between aortic and mitral PVL (85.7% vs. 79.2%, p = 0.478). Mean follow-up duration was 20 ± 4 months. At the last available follow-up, 53 of 76 patients (69.7%) were alive. Survival did not differ significantly according to the primary indication for the intervention (p = 0.827): 27 of 42 patients in the hemolysis group (64.3%) and 26 of 34 patients in the heart failure group (76.5%) were alive. By contrast, survival differed significantly according to PVL location (p = 0.007), with 25 of 28 patients with aortic PVL (89.3%) and 28 of 48 patients with mitral PVL (58.3%) alive at the last follow-up. In the subgroup of 42 patients with hemolysis, LDH decreased from 1289 ± 540 IU/L before the intervention to 901 ± 235 IU/L at 1 month, although this change was not statistically significant (p = 0.141). A statistically significant reduction was observed from 6 months onward and was maintained through 24 months, when LDH reached 504 ± 109 IU/L (p = 0.010).Hemoglobin increased from 9.34 ± 1.10 g/dL before the intervention to 10.03 ± 1.36 g/dL at 1 month (p = 0.009) and to 11.37 ± 1.69 g/dL at 24 months (p = 0.001). Indirect bilirubin decreased from 2.52 ± 1.99 mg/dL before the intervention to 1.50 ± 2.10 mg/dL at 1 month (p = 0.001) and to 0.74 ± 0.41 mg/dL at 24 months (p = 0.004). Transfusion requirement decreased from 26 patients (61.9%) before the intervention to 7 patients (16.7%) at 6 months after TPVLC (p = 0.009). TPVLC-related hemolysis occurred in 3 patients (7.1%). Conclusions: TPVLC was associated with high rates of technical and clinical success, a significant reduction in PVL severity, and improvement in patients’ functional status. The primary indication for the intervention was not associated with significant differences in technical success, clinical success, or survival. Aortic PVL location was associated with more favorable mid-term survival compared with mitral PVL. In patients with hemolysis, TPVLC was associated with significant and sustained improvement in hematologic parameters and a substantial reduction in transfusion requirement.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Lytra, Thekla
- Λύτρα, Θέκλα
Subjects
dc:subject × 14- Παραβαλβιδική ανεπάρκεια
- Διακαθετηριακή σύγκλειση παραβαλβιδικής ανεπάρκειας
- Αιμόλυση
- Καρδιακή ανεπάρκεια
- Paravalvular leak
- Transcatheter paravalvular leak closure
- Hemolysis
- Heart failure
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Καρδιολογία και Καρδιοαγγειακά νοσήματα
- Clinical Medicine
- Medical and Health Sciences
- Cardiology and Cardiovascular Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/62738